Enterome to Present Three Abstracts on its Novel OncoMimics™ Cancer Immunotherapies at ASCO 2022
May 27, 2022 – Drug Delivery –
Paris, France – May 27, 2022: Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announced the publication of three abstracts related to its OncoMimcs™ pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy, ahead of poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually.
Enterome will present clinical proof-of-concept data from its most advanced OncoMimics™ drug candidate, EO2401, a therapeutic cancer vaccine candidate currently in clinical development for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial, EOGBM1-18) and for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma (SPENCER trial, EOADR1-19).
A third poster describing the Phase 1/2 trial (SIDNEY, EONHL1-20) with Enteromeís second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma will also be presented at ASCO.
Details of the poster presentations and session are as follows:
ROSALIE Trial (EOGBM1-18)
ï Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma
ï Track: Central Nervous System Tumors
ï Abstract number: #2034
ï Date and Time: Sunday, June 5, 8:00 AM-11:00 AM CDT
ï Presenter: Professor Wolfgang Wick, Universit‰tsklinikum Heidelberg and German Cancer Research Center, Heidelberg, Germany
ï Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC)
ï Track: Genitourinary CanceróKidney and Bladder
ï Abstract number: #4596 ï Date and Time: Saturday, June 4, 1:15 PM-4:15 PM CDT
ï Presenter: Professor Vivek Subbiah, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX
ï Title: A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma
ï Poster session: Hematologic Malignancies/Lymphoma and Chronic Lymphocytic Leukemia
ï Poster number: #TPS7586
ï Date and Time: Saturday, June 4, 8:00 -11:00 AM CDT
ï Authors: Zinzani, P.L et al
